Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical trials of plecanatide, a treatment for patients with constipation-predominant irritable bowel syndrome. The trial is being conducted at 70 sites in the U.S. and includes 350 patients. Parexel International (PRXL -2%) is the contract research organization for the trial.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs